Stalling and shifting: China's leading medical device company experiences growing pains

【By Wang Li / Edited by Zhou Yuanfang】

For Mindray Medical (300760.SZ), 2025 is a year that requires a redefinition of growth. The company, widely hailed in the industry as “China’s number one medical device firm,” delivered its first “double decline” performance since listing in its 2025 annual report: operating revenue of RMB 33.282 billion, down 9.38% year over year; and net profit attributable to shareholders of RMB 8.136 billion, down 30.28% year over year.

Behind the surface numbers lies a glimpse of a deeper adjustment underway in China’s medical device industry. The DRG/DIP payment reform, the centralized volume-based procurement for in vitro diagnostic reagents, and the rollout of policies for cross-recognition of lab results—these measures have densely landed in succession, pushing the medical device sector centered on equipment and in vitro diagnostic reagents into a period of pain. Mindray’s domestic business achieved full-year revenue of RMB 15.632 billion, a sharp 22.97% drop year over year, nearly mirroring the common pressure faced by the entire industry.

However, this annual report is not only filled with dark clouds. International business revenue reached RMB 17.650 billion, up 7.40% year over year, and its share of total revenue first exceeded 53%. In 2025, Mindray’s revenue center of gravity officially crossed the internal-external balance point: it began to face the outside world in the posture of a truly globalized enterprise. Europe’s market grew 17% year over year; the emerging business segments (minimally invasive surgery, minimally invasive interventional procedures, and animal healthcare) grew 38.85% year over year; and gross margin reached 63.74%. Against the backdrop of overall downturn, the two growth curves look especially prominent.

Even more noteworthy is the strategic signal the company is sending through its positioning: R&D spending of RMB 3.929 billion, accounting for 11.80% of revenue, hitting a record high; the “equipment + IT + AI” digital- and intelligence-enabled medical ecosystem landed at global top institutions such as Shanghai Renji Hospital and Saudi Arabia’s largest virtual hospital; total dividends for the year reached RMB 5.310 billion, with a payout ratio of 65.27%. Over the seven years since listing, cumulative returns to investors exceeded RMB 37.7 billion—more than six times the amount raised in the IPO. On the surface, it is near-term earnings pressure; at a deeper level, it is structural strategic reshaping.

The downside is deep—where is the turnaround?

Procurement program pressure: domestic scale down, share up

In China’s domestic medical device market in 2025, nearly all mainstream manufacturers are unable to stay out of it. Mindray’s domestic business delivered full-year revenue of RMB 15.632 billion, down 22.97% from RMB 20.292 billion in 2024. But if we place this decline in the coordinate system of a longer policy cycle, we find it is an inevitable result of multiple policy forces converging—not the essence of a fundamental weakening in the company’s competitiveness.

In 2025, China’s domestic medical device industry simultaneously faced three layers of policy pressure. First, DRG/DIP payment system reforms continued to deepen, bringing hospital laboratory testing behaviors into the framework of cost control; both the single-use quantity and unit price of various lab test items were compressed. Second, the centralized procurement coverage for in vitro diagnostic reagents kept expanding; tender prices for core categories such as chemiluminescence and blood analysis fell sharply, with some category price declines exceeding 50%. Third, the advancement of cross-recognition of lab results reduced demand for duplicate testing, further shrinking actual reagent consumption. With all three effects combined, they formed a concentrated drag on Mindray’s in vitro diagnostic domestic revenue.

Medical imaging and life information & support services also were not spared. Due to hospitals’ overall contraction in capital expenditure budgets, Mindray’s medical imaging revenue fell 18.02% year over year, and life information & support’s domestic revenue declined 19.80% year over year. The decision chain for equipment procurement at hospitals became longer and approvals stricter: delivery cycles for large-hospital orders were delayed, while smaller hospitals, under operating pressure, proactively cut back procurement plans.

A shrinking scale does not equate to a degradation of competitiveness. The annual report data reveals an counterintuitive phenomenon: against the backdrop of an industry-wide contraction, Mindray’s domestic market share actually increased noticeably. The logic behind it is as follows: centralized procurement policies deal a fundamental blow to foreign brands’ price advantages. Manufacturers such as Roche and Abbott saw their profit margins compressed significantly within the compliant centralized procurement price ranges, while Mindray, backed by a more flexible local supply chain and more complete channel coverage, took a relatively more proactive position in price competition. Accelerated import substitution means the beneficiaries are domestic leading firms with complete product matrices.

Worth noting is that in the reporting period, Mindray’s domestic emerging businesses recorded high growth. Segments such as minimally invasive surgery and animal healthcare—areas less affected by centralized procurement policies—showed clear resilience. The combined revenue of domestic emerging businesses and in vitro diagnostics has already accounted for nearly 70% of domestic business revenue. Structural change is quietly happening: moving from a single model highly dependent on centralized equipment procurement to a model driven by recurring consumables revenue and high-growth emerging businesses.

On the profitability side, overall gross margin fell by 2.81 percentage points to 60.33%, reflecting the real impact of lower centralized procurement prices and product mix adjustments. It is worth noting that this gross margin level remains a high-quality figure among global medical device companies, comparable to international leaders such as Medtronic and Stryker. This indicates that Mindray’s core product pricing power has not been fundamentally shaken. Domestic selling expense, while declining with revenue, still remains at an absolute scale of RMB 5.145 billion. Releasing operating leverage still requires support from an even larger revenue scale.

Entering the “GPS” top three giants’ strongholds in Europe: growth of 17%

In 2025, Mindray’s international business revenue was RMB 17.650 billion, up 7.40% year over year, and its share of total revenue first exceeded 53%. The significance of this proportion goes beyond the financials itself—it means Mindray has officially moved beyond a development stage where domestic revenue is primary and international revenue secondary, entering a new competitive landscape where globalization is the main axis. For Mindray, this is both a strategic milestone and a double-edged sword: international business dominance implies higher exposure to exchange-rate risk, geopolitical risk, and the cost of localized management.

The international market environment in 2025 was not friendly. High interest rates and inflation suppressed healthcare capital expenditure in emerging-market countries. Geopolitical risks such as the Russia-Ukraine conflict and the situation in the Middle East continued to disrupt regional orders; currency depreciation also eroded parts of operations through FX translation. In financial expenses, increased FX losses alongside reduced interest income led to financial expenses rising by about 34% year over year. Against this backdrop, Mindray still achieved positive growth, and Europe—at a 17% growth rate—became the brightest regional highlight.

Europe’s breakthrough is strategically significant. Traditionally, Europe has been the home ground of the “GPS” top three giants—Philips, Siemens, and GE Healthcare. Local brands built strong moats by relying on long-standing customer relationships and certification barriers accumulated over time. Mindray’s ability to achieve another 17% growth in 2025 on top of high growth in 2024 indicates that it has established a level of recognition in the European market.

From a strategy perspective, Mindray’s internationalization has evolved from an early low-cost substitution route relying on price competition to a value-based healthcare route driven by digital and intelligence-enabled solutions. The “equipment + IT + AI” ecosystem, emphasized in the annual report, with deployment cases at institutions such as Indonesia’s Mayapada Medical Group and Saudi Arabia’s SEHA virtual hospital, essentially uses systems integration capabilities to replace competition on single equipment alone. It uses long-term services to replace one-time sales and delivery. This shift increases the contract value per customer and strengthens customer stickiness, but it also means a longer market expansion cycle and higher upfront delivery costs.

By deepening strategic cooperation in patient monitoring with Medtronic and signing comprehensive strategic cooperation agreements with Asia’s largest private healthcare group IHH across multiple markets including Malaysia, India, and Turkey, Mindray’s strategic intent becomes visible: it is trying to accelerate penetration into high-end markets by leveraging top institutions’ brand endorsements and its channel network. This path is more resource-efficient than building channels entirely from scratch. But how to maintain space for independent brand building within collaborations and avoid being reduced to an OEM role will be an ongoing strategic challenge.

The intensity of investment in its localization strategy is also evident. The company has set up 64 overseas subsidiaries in about 40 countries, and among more than 3,000 overseas employees, over 90% are local hires. In addition to five overseas R&D centers, 14 countries have planned localized production projects, of which 11 have already been launched. Localized production not only helps to avoid trade barriers and tariff risks; under the current backdrop of accelerating deglobalization, it also has greater long-term strategic defensive value. However, the upfront capital investment required for localized production cannot be underestimated. For regional markets that are still climbing the path toward profitability, it will create short-term margin dilution pressure.

What needs to be viewed rationally is that the regional structure of international business still shows clear imbalance. Developing-country markets still account for most of international revenue, while penetration into high-profit, high-end markets in Europe and the U.S. remains at a relatively early stage. The annual report admits that the average market share of its life information & support business in overseas markets is still lower than the level in domestic markets, and the overseas market share of ultrasound products is still in the single digits. Especially in North America, the complexity of device registration cycles, the complexity of hospital procurement decision chains, and the defensive strategies of local competitors all make large-scale penetration more difficult than in other markets.

Emerging markets bring both opportunities and risks: demand for medical infrastructure construction is strong across Asia, Africa, and Latin America, and Mindray’s value-for-money positioning has a built-in advantage. But these markets often have long government payment cycles, higher accounts receivable risk, and complex foreign-exchange controls. In 2025, credit impairment losses were RMB 196 million and asset impairment losses were RMB 336 million. With international business continuing to expand, this risk needs ongoing attention. From a five-year longitudinal trajectory, Mindray’s international revenue rose from about RMB 7.0 billion in 2020 to RMB 17.650 billion in 2025—about 2.5 times growth. Internationalization is a real and sustainable growth driver. However, turning “qualitative change” into “quantitative change” still requires time.

From “selling equipment” to “intelligent medicine”: Mindray’s surgical robot ambitions

In 2025, Mindray’s emerging business segments (minimally invasive surgery, minimally invasive interventional procedures, and animal healthcare) became the most distinct growth signal in an annual report marked by overall decline. The segment delivered revenue of RMB 5.378 billion, representing a year-over-year growth rate of 38.85%. The segment accounts for about 16% of the company’s total revenue, and gross margin is as high as 63.74%—the highest across all lines of business, higher than in vitro diagnostics at 58.33% and life information & support at 59.37%. Behind the numbers is Mindray’s strategic logic for building a second growth curve.

The minimally invasive surgery business focuses on laparoscopic surgery scenarios. It has launched the UX series of 4K+3D+NIR fluorescence laparoscopic imaging systems, and built a complete product matrix around high-value consumables such as energy platforms, staplers, and trocars, covering key clinical departments including general surgery, thoracic surgery, gynecology, and urology.

Even more noteworthy is that the annual report explicitly states the company has completed its underlying capability layout for surgical robots. Building on its technical accumulation in three areas—laparoscopy, energy platforms, and surgical instruments—the company will launch surgical robot products. This is the first time Mindray has formally announced its strategic direction for surgical robots in an official annual report, indicating it is formally entering the high-end surgical robot track led by the da Vinci system (Intuitive Surgical). This market is large globally, but the technical barriers are extremely high. Mindray’s timing and path choice for entry will be one of the major strategic propositions worth tracking continuously over the coming years.

The minimally invasive interventional business relies on Huatai Medical (Mindray completed its controlling stake acquisition in 2023). It focuses on building out electphysiology, coronary access pathways, and peripheral vascular interventional procedures. In the reporting period, the 3D atrial fibrillation PFA (pulsed field ablation) and RFA systems and their supporting consumables received NMPA approval and entered clinical use. Mindray’s products in the field of arrhythmia interventional therapy have moved from R&D to commercialization and are now formally entering the contest for inventory-market share led by international manufacturers such as Medtronic, Abbott, and Boston Scientific. PFA is currently among the most cutting-edge procedural directions in cardiac electrophysiology—technically challenging but with strong market growth potential. It should be noted that Huatai Medical is still in the stage of integration and enhancement, and the realization of integration-and-synergy effects is expected to require more than three years. In the short term, its contribution to overall performance from incremental gains will be limited.

Animal healthcare is the emerging business with the clearest market logic and the most certain business model among the three segments. Mindray extends its R&D accumulation in human medical devices horizontally to veterinary clinical scenarios. Overseas revenue already accounts for about 80% of total animal healthcare revenue. Since its inception, this business has been planned from a global perspective, effectively avoiding direct disruptions from domestic medical policies. Given the industry backdrop of ongoing expansion in the global pet economy and rising demand for standardized veterinary testing, animal healthcare is one of the few tracks where Mindray can achieve natural growth without the pressure of centralized procurement. It is also a typical example of reusing cross-domain R&D capabilities.

The strategic ambition behind the digital- and intelligence-enabled medical ecosystem is also worth examining separately. Using “equipment + IT + AI” as the core framework, Mindray is rolling out specific products such as the large model for critical care medicine (Qiyuan), lab testing large models, and ultrasound AI assistants, and is transforming itself from a hardware manufacturer into a digital intelligence-enabled hospital collaboration partner. Shanghai Renji Hospital’s perioperative large-model solutions reduce chart entry time; Beijing University Shenzhen Hospital’s emergency and critical-care digital intelligence integrated solution; and Southern Medical University Shenzhen Hospital’s sample review time improved by about 30 times—these are deployment cases supported by real clinical results, not just concept demonstrations. Projects such as a province-wide ultrasound “one network” in Anhui and regional medical laboratory centers in Dali, among others, reveal the market space into which it is deeply embedded in the Healthy China strategy.

But the commercialization and deployment of the AI ecosystem still involves many uncertainties. The hospital informatization market landscape is complex. Vendors such as Winning Health and Neusoft have long occupied the core data nodes of hospitals with their HIS/LIS systems. For Mindray’s AI large models to achieve multi-source data interoperability, it must cooperate deeply with these existing IT systems—covering both technical interface compatibility and the alignment of commercial interests. In addition, AI product pricing logic is fundamentally different from traditional equipment sales. How to achieve reasonable pricing and ongoing subscription-like charging for AI services under the constraints of public hospital procurement is still an industry business-model challenge that remains unresolved. Domestic AI medical regulatory policies are currently in the rulemaking stage, and the uncertainty in product compliance paths also constitutes a potential risk.

The scale of R&D investment is the ballast stone for Mindray’s sustained competitiveness, but it is also a variable contributing to financial pressure in the current period. In 2025, R&D expenses were RMB 3.929 billion, or 11.80% of revenue, up further from 10.91% in 2024. Worth noting is that from 2023 to 2025, the cumulative total R&D investment over three years exceeded RMB 11.7 billion. The absolute scale is roughly flat, but due to revenue contraction, the expense ratio rose passively, exerting additional downward pressure on profit margins.

Looking across Mindray’s overall strategic layout: it uses internationalization to hedge domestic policy pressure, uses emerging businesses to hedge traditional business maturity, and uses the digital- intelligence ecosystem to hedge pure hardware competition. Based on 2025 data, this hedging mechanism has begun to take effect. Whether it can fully bridge and form a new scale effect within the medium term is what Mindray needs—requires the dual realization of time and execution capacity.

A massive flow of information and precise analysis—on the Sina Finance app